The quarter came in well below the market’s revenue bar. Published consensus was approximately $148.5 million of quarterly revenue and $(0.01) of EPS; Immunocore delivered $115.9 million and $(0.02), respectively. Revenue therefore missed by roughly 22%, while the EPS miss was modest.
| $ millions, except per-share data | Q2 2026 | Q2 2025 | Year-to-date 2026 | Year-to-date 2025 |
|---|---|---|---|---|
| KIMMTRAK net sales | 115.9 | 98.0 | 222.6 | 191.8 |
| Growth | 18% | — | 16% | — |
| R&D expense | 73.9 | 69.0 | 135.1 | 125.5 |
| Operating income (loss) | (3.0) | (14.9) | 4.3 | (18.5) |
| Net income (loss) | (0.8) | (10.3) | 12.2 | (5.3) |
| Diluted EPS | (0.02) | (0.20) | 0.23 | (0.11) |
| Operating cash flow | — | — | 2.2 | 26.4 |
(Financial Highlights) KIMMTRAK is still growing, but not fast enough for the expectation embedded in the quarter. Sales rose 18% year over year, led by higher U.S. and international volume, yet the absolute result was far below the published consensus. The filing does not provide a new full-year sales outlook, so there is no raised forecast or other forward signal to repair the miss. (Financial Highlights; KIMMTRAK business update)
The improved profit headline is less meaningful than it looks. Q2’s net loss narrowed to $0.8 million from $10.3 million, but the company still posted a $3.0 million operating loss, while R&D increased to $73.9 million as three Phase 3 programs advanced. First-half profitability turned positive largely because revenue growth and non-operating items outweighed spending; it does not yet demonstrate a durable operating-profit model. (Income Statement)
Cash remains substantial, but near-term cash conversion weakened. Cash, cash equivalents, and marketable securities totaled $880.2 million at June 30, up only $16.0 million from year-end, while first-half operating cash generation fell to $2.2 million from $26.4 million. The company also expects to pay approximately $120 million of sales-related rebate accruals in the second half, reducing the practical cushion relative to the headline balance. (Balance Sheet; Cash Flow statement; Financial Highlights)
The pipeline update is supportive but mostly confirms existing milestones rather than creating a new catalyst. Brenetafusp’s 160-microgram monotherapy cohort showed a 17% response rate and 67% disease-control rate versus 6% and 56% at 40 micrograms, supporting the selected Phase 3 dose; however, those data were already presented at ASCO. TEBE-AM enrollment is nearing 540 patients, with topline data possible as early as late 2026, but the filing offers no new efficacy result or change in timing. (Brenetafusp clinical update; KIMMTRAK pipeline update)
Net read: the financial miss outweighs the pipeline reassurance. A growing commercial product, positive first-half earnings, and steady late-stage trial execution are constructive, but the quarter’s core observable metric—KIMMTRAK sales—fell materially short of consensus, with no offsetting guidance increase or new clinical data. That leaves the filing narrowly focused on execution risk rather than expanding near-term expectations.
Read the original 8-K on SEC EDGAR ↗